Tokyo, Japan - August 1, 2022 - Medical and Biological Laboratories Co., Ltd. (President & CEO: Kimimasa Yamada, “MBL”), a JSR Life Sciences Company, announced that MEBGEN™ BRAF Kit, an in vitro diagnostic reagent, was approved for detection of BRAF gene mutations (V600E or V600K) by the Ministry of Health, Labour and Welfare (MHLW) for production and marketing in Japan on July 7, 2022.
MEBGEN™ BRAF Kit was developed as a companion diagnostic for multiple anti-cancer agents in melanoma. The MEBGEN BRAF Kit is expected to be an important clinical diagnostic in guiding personalized medicine for patients with melanoma.
Purpose of use: Detection of BRAF gene mutations (V600E or V600K) in DNA extracted from cancer tissue
Head Quarters: SUMITOMO FUDOSAN SHIBADAIMON NICHOME BLDG. 2-11-8 Shibadaimon, Minato-ku, Tokyo 105-0012 Japan
Contact form: https://www.mblbio.com/e/contact/
MBL was established in 1969 as the first antibody manufacturer in Japan, and researches, develops, manufactures, and sells reagents of in vitro diagnostics and reagents for basic research. MBL has now expanded its business not only to the immunological field but also to the field of genetic diagnosis. In the field of oncology, MBL is contributing to personalized medicine by developing companion diagnostics. For more information, please visit https://www.mblbio.com/cdx/
Contact details
-
Download vCard
- Sarah Martin-Tyrrell
-
JSR Life Sciences Company Inquiries
Senior Manager, PR and Content - sarah.martin-tyrrell@crownbio.com
Related topics
Related news
MBL Co-sponsors a Seminar on MEBRIGHT™ genitalium Plus DR Kit at the 98th JAID / the 72nd JSC Conference
MBL to co-sponsor a seminar on MEBRIGHT™ genitalium Plus DR Kit at the 98th JAID/72nd JSC Conference, focusing on STD treatment advancements. Learn more on June 27th, 2024.
MBL announces exclusive license agreement for Anti-Integrin αvβ6 Antibody with Immune-related Adverse Events colitis
MBL has announced that it has entered into an exclusive license agreement with Kyoto University and Kindai University regarding the detection of Anti-Integrin αvβ6 autoantibodies as an indicator of...
MEBGEN™ BRAF 2 Kit Receives MHLW Approval as a Companion Diagnostic for Use with Patients with Thyroid Cancer
With this approval, the MEBGEN™ BRAF 2 Kit is expected to contribute to the timely personalized treatment for patients with radically unresectable thyroid cancer based on the presence or absence of...
Notice of Approval for First-Class Marketing License for Medical Devices
With the acquisition of the First-Class Marketing License for Medical Devices, MBL will be able to market highly controlled medical devices, including genetic testing systems using NGS.
Launch of a New Chemiluminescence Immunoassay Analyzer “iStar500”
The iStar is a highly automated mono-test analyzer based on CLIA technology. The compact & integrated design, combined with highly sensitive CLIA technology, makes it an ideal choice for emergency ...